M

Mankind Pharma Ltd
NSE:MANKIND

Watchlist Manager
Mankind Pharma Ltd
NSE:MANKIND
Watchlist
Price: 2 350.25 INR -0.92%
Market Cap: 969.7B INR

Mankind Pharma Ltd
Investor Relations

Mankind Pharma Ltd. has carved a unique niche in the pharmaceutical landscape of India, emerging as a formidable entity through an intriguing blend of affordability and accessibility. Founded in 1995 by R. C. Juneja, the company has steadily grown its portfolio to encompass a vast range of pharmaceutical products spanning prescription medications, over-the-counter (OTC) drugs, and consumer healthcare goods. Operating with a distinctive business model rooted in the ethos of delivering quality medicine at affordable prices, Mankind Pharma reaches deep into the densely populated tier II and tier III cities of India, ensuring that healthcare is accessible to the masses who need it the most. This strategic outreach, coupled with strong marketing and distribution networks, serves as a cornerstone of its business success.

The company’s financial health is buoyed by its diversified product range, which caters to multiple therapeutic areas including antibiotics, cardiovascular, antifungal, and gastrointestinal, among others. Their robust R&D initiatives further reinforce their competitive edge, enabling them to continually introduce new and effective products that resonate with both healthcare providers and consumers. Revenue streams are not just confined to domestic borders; Mankind Pharma has been expanding its footprint internationally, penetrating markets across Asia, Africa, and the Americas. By striking a strategic balance between volume-driven pricing models and extensive market reach, Mankind Pharma not only emphasizes profitability but also solidifies its commitment to public health initiatives globally, thus creating a sustainable and progressive business trajectory.

Show more
Loading

Earnings Calls

2024 Q4
Feb 13, 2025
Show Transcript
Previous
Next
Casella Waste Systems Forecasts Strong Growth Through Acquisitions and Operational Efficiency
2024 Q4
Feb 13, 2025

In 2024, Casella Waste Systems delivered impressive growth with adjusted EBITDA rising 20% and free cash flow increasing by 23%. The company closed eight acquisitions generating over $200 million in annual revenues and projects 2025 revenue between $1.775 billion and $1.805 billion, representing a 15% growth rate. The adjusted EBITDA is expected to be between $410 million and $425 million. The company is optimistic about modest volume growth despite facing slight declines in certain sectors, focusing on operational efficiencies and enhancing automated solutions to improve margins further.

Show Full Analysis

Management

Mr. Ramesh C. Juneja
Executive Chairman
No Bio Available
Mr. Sheetal Arora
CEO & Whole-Time Director
No Bio Available
Mr. Rajeev Juneja
Vice Chairman & MD
No Bio Available
Mr. Satish Kumar Sharma
Whole-Time Director
No Bio Available
Mr. Ashutosh Dhawan MBA
Chief Financial Officer
No Bio Available
Mr. Arjun Juneja
Chief Operating Officer
No Bio Available
Mr. Chanakya Juneja
Director of Technology
No Bio Available
Mr. Pramod Gokhale
President - Group Chief Information Officer
No Bio Available
Dr. Anil Kumar
Chief Scientific Officer (Research Centre)
No Bio Available
Mr. Abhishek Agarwal
Head of Investor Relations
No Bio Available

Contacts

Address
DELHI
New Delhi
262, Okhla Industrial Estate
Contacts